FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3201448731> ?p ?o ?g. }

• W3201448731 endingPage "100055" @default.
• W3201448731 startingPage "100055" @default.
• W3201448731 abstract "The coronavirus disease 2019 (COVID-19) pandemic has undoubtedly become a global crisis. Consequently, discovery and identification of new or known potential drug candidates to solve the health problems caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have become an urgent necessity. This current research study sheds light on the possible direct repurposing of the antirheumatic drug teriflunomide to act as an effective and potent anti-SARS-CoV-2 agent. Herein, an interesting computational molecular docking study of teriflunomide, to investigate and evaluate its potential inhibitory activities on the novel coronaviral-2 RNA-dependent RNA polymerase (nCoV-RdRp) protein, was reported. The docking procedures were accurately carried out on nCoV-RdRp (with/without RNA) using the COVID-19 Docking Server, through adjusting it on the small molecule docking mode. Remdesivir and its active metabolite (GS-441524) were used as the active references for the comparison and evaluation purpose. Interestingly, the computational docking analysis of the best inhibitory binding mode of teriflunomide in the binding pocket of the active site of the SARS-CoV-2 RdRp revealed that teriflunomide may exhibit significantly stronger inhibitory binding interactions and better inhibitory binding affinities (teriflunomide has considerably lower binding energies of -9.70 and -7.80 ​kcal/mol with RdRp-RNA and RdRp alone, respectively) than both references. It was previously reported that teriflunomide strongly inhibits the viral replication and reproduction through two mechanisms of action, thus the results obtained in the present study surprisingly support the double mode of antiviral action of this antirheumatic ligand. In conclusion, the current research paved the way to practically prove the hypothetical theory of the promising abilities of teriflunomide to successfully attack the SARS-CoV-2 particles and inhibit their replication in a triple mode of action through integrating the newly-discovered nCoV-RdRp-inhibiting properties with the previously-known two anticoronaviral mechanisms of action. Based on the previous interesting facts and results, the triple SARS-CoV-2/sextet COVID-19 attacker teriflunomide can further undergo in vitro/in vivo anti-COVID-19 assays together with preclinical/clinical studies and trials in an attempt to evaluate and prove its comprehensive pharmacological activities against the different SARS-CoV-2 strains to be effectively used in COVID-19 therapy in the very near future." @default.
• W3201448731 created "2021-09-27" @default.
• W3201448731 creator A5027641532 @default.
• W3201448731 date "2021-01-01" @default.
• W3201448731 modified "2023-10-15" @default.
• W3201448731 title "Teriflunomide: A possible effective drug for the comprehensive treatment of COVID-19" @default.
• W3201448731 cites W1983382084 @default.
• W3201448731 cites W2047977738 @default.
• W3201448731 cites W2049498103 @default.
• W3201448731 cites W2154147815 @default.
• W3201448731 cites W2158589288 @default.
• W3201448731 cites W2228301361 @default.
• W3201448731 cites W2588373723 @default.
• W3201448731 cites W2914796231 @default.
• W3201448731 cites W2967237262 @default.
• W3201448731 cites W2999409984 @default.
• W3201448731 cites W3003788575 @default.
• W3201448731 cites W3008142620 @default.
• W3201448731 cites W3008937361 @default.
• W3201448731 cites W3012455685 @default.
• W3201448731 cites W3022734398 @default.
• W3201448731 cites W3023915741 @default.
• W3201448731 cites W3036749055 @default.
• W3201448731 cites W3043467580 @default.
• W3201448731 cites W3047125225 @default.
• W3201448731 cites W3092397615 @default.
• W3201448731 cites W3093383252 @default.
• W3201448731 cites W3107020155 @default.
• W3201448731 cites W3119308228 @default.
• W3201448731 cites W3121017292 @default.
• W3201448731 cites W3121896770 @default.
• W3201448731 cites W3156006935 @default.
• W3201448731 cites W3159177617 @default.
• W3201448731 cites W3160607436 @default.
• W3201448731 cites W3170142578 @default.
• W3201448731 cites W3171997179 @default.
• W3201448731 cites W3185414884 @default.
• W3201448731 doi "https://doi.org/10.1016/j.crphar.2021.100055" @default.
• W3201448731 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34870153" @default.
• W3201448731 hasPublicationYear "2021" @default.
• W3201448731 type Work @default.
• W3201448731 sameAs 3201448731 @default.
• W3201448731 citedByCount "26" @default.
• W3201448731 countsByYear W32014487312022 @default.
• W3201448731 countsByYear W32014487312023 @default.
• W3201448731 crossrefType "journal-article" @default.
• W3201448731 hasAuthorship W3201448731A5027641532 @default.
• W3201448731 hasBestOaLocation W32014487311 @default.
• W3201448731 hasConcept C103637391 @default.
• W3201448731 hasConcept C121587506 @default.
• W3201448731 hasConcept C142724271 @default.
• W3201448731 hasConcept C159047783 @default.
• W3201448731 hasConcept C159110408 @default.
• W3201448731 hasConcept C185592680 @default.
• W3201448731 hasConcept C203014093 @default.
• W3201448731 hasConcept C2776036978 @default.
• W3201448731 hasConcept C2777648638 @default.
• W3201448731 hasConcept C2777703276 @default.
• W3201448731 hasConcept C2779134260 @default.
• W3201448731 hasConcept C2780035454 @default.
• W3201448731 hasConcept C2780640218 @default.
• W3201448731 hasConcept C3008058167 @default.
• W3201448731 hasConcept C41685203 @default.
• W3201448731 hasConcept C524204448 @default.
• W3201448731 hasConcept C55493867 @default.
• W3201448731 hasConcept C70721500 @default.
• W3201448731 hasConcept C71924100 @default.
• W3201448731 hasConcept C86803240 @default.
• W3201448731 hasConcept C98274493 @default.
• W3201448731 hasConceptScore W3201448731C103637391 @default.
• W3201448731 hasConceptScore W3201448731C121587506 @default.
• W3201448731 hasConceptScore W3201448731C142724271 @default.
• W3201448731 hasConceptScore W3201448731C159047783 @default.
• W3201448731 hasConceptScore W3201448731C159110408 @default.
• W3201448731 hasConceptScore W3201448731C185592680 @default.
• W3201448731 hasConceptScore W3201448731C203014093 @default.
• W3201448731 hasConceptScore W3201448731C2776036978 @default.
• W3201448731 hasConceptScore W3201448731C2777648638 @default.
• W3201448731 hasConceptScore W3201448731C2777703276 @default.
• W3201448731 hasConceptScore W3201448731C2779134260 @default.
• W3201448731 hasConceptScore W3201448731C2780035454 @default.
• W3201448731 hasConceptScore W3201448731C2780640218 @default.
• W3201448731 hasConceptScore W3201448731C3008058167 @default.
• W3201448731 hasConceptScore W3201448731C41685203 @default.
• W3201448731 hasConceptScore W3201448731C524204448 @default.
• W3201448731 hasConceptScore W3201448731C55493867 @default.
• W3201448731 hasConceptScore W3201448731C70721500 @default.
• W3201448731 hasConceptScore W3201448731C71924100 @default.
• W3201448731 hasConceptScore W3201448731C86803240 @default.
• W3201448731 hasConceptScore W3201448731C98274493 @default.
• W3201448731 hasLocation W32014487311 @default.
• W3201448731 hasLocation W32014487312 @default.
• W3201448731 hasLocation W32014487313 @default.
• W3201448731 hasOpenAccess W3201448731 @default.
• W3201448731 hasPrimaryLocation W32014487311 @default.
• W3201448731 hasRelatedWork W146300602 @default.
• W3201448731 hasRelatedWork W1930623285 @default.
• W3201448731 hasRelatedWork W1999913066 @default.

• next